ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives $81.00 Average PT from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been assigned an average rating of “Buy” from the four ratings firms that are covering the company, Marketbeat.com reports. Four investment analysts have rated the stock with a buy rating. The average 1 year target price among brokerages that have covered the stock in the last year is $81.00.

A number of analysts have recently weighed in on the stock. Guggenheim restated a “buy” rating and issued a $77.00 price target on shares of ANI Pharmaceuticals in a report on Tuesday, April 23rd. HC Wainwright lifted their target price on shares of ANI Pharmaceuticals from $83.00 to $87.00 and gave the stock a “buy” rating in a research note on Monday, May 13th. Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Finally, Truist Financial lifted their target price on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, March 1st.

Insider Buying and Selling

In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the sale, the senior vice president now owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, SVP Chad Gassert sold 20,000 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $67.25, for a total transaction of $1,345,000.00. Following the completion of the sale, the senior vice president now owns 253,226 shares of the company’s stock, valued at $17,029,448.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Christopher Mutz sold 2,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $61.61, for a total transaction of $123,220.00. Following the sale, the insider now directly owns 83,277 shares of the company’s stock, valued at approximately $5,130,695.97. The disclosure for this sale can be found here. In the last quarter, insiders sold 176,688 shares of company stock valued at $11,408,863. 12.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Pacer Advisors Inc. acquired a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at about $41,000. AJOVista LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $58,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at about $106,000. China Universal Asset Management Co. Ltd. lifted its position in ANI Pharmaceuticals by 361.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,367 shares of the specialty pharmaceutical company’s stock valued at $131,000 after buying an additional 1,854 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in ANI Pharmaceuticals in the fourth quarter valued at about $132,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Trading Up 2.2 %

NASDAQ ANIP opened at $64.19 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.12 and a current ratio of 3.95. The company has a market capitalization of $1.35 billion, a price-to-earnings ratio of 40.12 and a beta of 0.81. The company’s 50-day simple moving average is $64.28 and its two-hundred day simple moving average is $61.56. ANI Pharmaceuticals has a one year low of $48.20 and a one year high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, May 10th. The specialty pharmaceutical company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.16. The business had revenue of $137.43 million for the quarter, compared to the consensus estimate of $125.01 million. ANI Pharmaceuticals had a net margin of 6.87% and a return on equity of 17.15%. Equities analysts forecast that ANI Pharmaceuticals will post 3.34 EPS for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.